Tumor development, or tumorigenesis, broadly describes the process by which normal cells gain malignant properties. Tumor development includes growth functions like cellular differentiation, proliferation, and metastasis.
Date: June 30, 2021 Time: 7:00am (PDT), 8:00am (EDT) Join us to discover how Optical genome mapping (OGM) mapping can help you in the characterization of complex samples. OGM is a non-sequen...
Date: June 24, 2021 Time: 9:00am PDT Currently, there are insufficient therapies to fully eradicate human cancer or predict who it will strike. Rational-drug design based on structural insi...
Date: June 16, 2021 Time: 8:00am PDT The MACSima™ Imaging Platform is the only complete solution for ultrahigh-content imaging of hundreds of markers, allowing you to understand the tu...
Date: June 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation...
Date: June 8, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Most deaths from ovarian and endometrial cancer are due to high-grade subtypes that metastasize before they are detectable by available...
Cells in their natural environment are surrounded by a complex extracellular matrix that provides structure and functional cues to the surrounding cells. Hydrogels can be used to approximate...
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its rec...
Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how...
Gene editing experts within MilliporeSigma’s Cell Design Studio™ provide premier custom cell line engineering services to create and deliver unique cell-based assays tailored for...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Learning Objectives: 1. Learn about why Luminex’s xMAP bead-based technology is the gold-standard in multiplexing, including how xMAP emerged as the leading multiplexing platform for l...
This webinar will highlight the research solutions that Miltenyi Biotec has to offer for those investigating the roles of Tregs, NK cells, and Macrophages in the context of the tumor microen...
Ovarian cancer is a deadly disease which is usually diagnosed in advanced stages. Our goal is to develop vaccines to prevent relapse. Natural Th17 T cells protect against recurrence followin...
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immuno...
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...
Date: May 18, 2021 Time: 7:00am PDT, 10:00am EDT Proteins encoded by mutant genes in cancers can be processed and presented on tumor cell surface by human leukocyte antigen (HLA) molecules,...
Learning Objectives: 1. Identify different kinds of genomic resources 2. Learn to apply the features available in genomic resources to cancer variant interpretation 3. Describe the importanc...
5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity...
Date: June 30, 2021 Time: 7:00am (PDT), 8:00am (EDT) Join us to discover how Optical genome mapping (OGM) mapping can help you in the characterization of complex samples. OGM is a non-sequen...
Date: June 24, 2021 Time: 9:00am PDT Currently, there are insufficient therapies to fully eradicate human cancer or predict who it will strike. Rational-drug design based on structural insi...
Date: June 16, 2021 Time: 8:00am PDT The MACSima™ Imaging Platform is the only complete solution for ultrahigh-content imaging of hundreds of markers, allowing you to understand the tu...
Date: June 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation...
Date: June 8, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Most deaths from ovarian and endometrial cancer are due to high-grade subtypes that metastasize before they are detectable by available...
Cells in their natural environment are surrounded by a complex extracellular matrix that provides structure and functional cues to the surrounding cells. Hydrogels can be used to approximate...
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its rec...
Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how...
Gene editing experts within MilliporeSigma’s Cell Design Studio™ provide premier custom cell line engineering services to create and deliver unique cell-based assays tailored for...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Learning Objectives: 1. Learn about why Luminex’s xMAP bead-based technology is the gold-standard in multiplexing, including how xMAP emerged as the leading multiplexing platform for l...
This webinar will highlight the research solutions that Miltenyi Biotec has to offer for those investigating the roles of Tregs, NK cells, and Macrophages in the context of the tumor microen...
Ovarian cancer is a deadly disease which is usually diagnosed in advanced stages. Our goal is to develop vaccines to prevent relapse. Natural Th17 T cells protect against recurrence followin...
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immuno...
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...
Date: May 18, 2021 Time: 7:00am PDT, 10:00am EDT Proteins encoded by mutant genes in cancers can be processed and presented on tumor cell surface by human leukocyte antigen (HLA) molecules,...
Learning Objectives: 1. Identify different kinds of genomic resources 2. Learn to apply the features available in genomic resources to cancer variant interpretation 3. Describe the importanc...
5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
